supplementary materials supplementary methods cell...
TRANSCRIPT
Supplementary Materials Banito et al. p1
SUPPLEMENTARY MATERIALS
SUPPLEMENTARY METHODS
Cell culture. EBV-transformed hB clones were maintained in RPMI supplemented with 10%
FCS, 2 mM L-glutamine and antibiotics (10 µg/ml Penicillin and Streptomycin). E14Tg2a
mouse ES cells were grown and maintained undifferentiated on irradiated SNL feeder layers.
ES cells were grown in KO-DMEM medium plus 10% FCS, non-essential amino acids, L-
glutamine, 2-mercaptoethanol, antibiotics and 1000 U/ml of leukaemia inhibitory factor
(ESGRO-LIF). Human ES cell lines H1, H7 and H9 cells were cultured as previously
described (Pereira et al. 2008).
Experimental Heterokaryons. Heterokaryons were generated by fusing ES cells and human
B-lymphocytes using 50% polyethylene glycol, pH 7.4 (PEG 1500; Roche Diagnostics,
Mannheim, Germany). The procedure has been described in detail on (Pereira et al. 2008).
For the experimental heterokaryons experiments the qRT-PCR was performed as described
in (Pereira et al. 2008). All primers used for the experimental heterokaryons experiments were
previously tested to assuage that were human-specific for genes and did not crossreact with
the murine counterpart. Primer sets used are listed in the Sup. Table II.
High Content Analysis. For the High Content Analysis (HCA), cells where plated in 96-well
plates (Nunc) and stained by immunofluorescence. Two fluorescence images corresponding
to DAPI and gene-primary antibody/AlexaFluor488-secondary antibody were acquired for
each condition with the InCell 1000 automated epifluorescence microscope at 20x
magnification (GE). HCA was performed using In Cell investigator Software (GE). For the
analysis, cells and nuclei of the cell were defined using the DAPI staining. The nuclei were
segmented using top-hat segmentation defining a minimum nucleus area of 100 µm2. To
define the cell segmentation a collar segmentation routine was used, specifying a ratio of
1µm. To define the expression of the analyzed proteins by cell, the average intensity of pixels
in the reference channel (Alexa488) within the defined nuclear region (Object Nuclear
Intensity) was measured. Once each cell has associated a nuclear intensity for the specific
expression, a threshold filter defining positive and negative expressing cells was set.
Threshold filter uses a histogram for data visualization (Sup. Fig 4A-C). To specify the filter
settings the nuclear intensity measure was selected. The threshold filter defining cells with
nuclear intensities above or below a given value as positive or negative respectively for the
expression of the protein was set. The cut-off of the filter was set as follows: first expression
in the control was measured (i.e. p16INK4a expression in wells with empty vector infected cells,
Sup. Fig 4A) to define the negative population (red population on the histogram). Secondly,
the analysis of the positive control (i.e p16INK4a expression in wells with RasV12 infected cells,
Sup. Fig 4B) was performed to define the high expressing population (green population of the
Supplementary Materials Banito et al. p2
histogram). Once the cut-off was set up, the analysis of the whole experiment was carried out
(Sup. Fig 4C). As a result, the program assigns to each cell the definition of positive or
negative for the expression of the protein analyzed (i.e. p16INK4a positive (p16) and negative
(neg) expressing cells in empty vector versus RasV12 infected cells, Sup. Fig 4D), and
generates a percentage of both cell populations (positive and negative) per well. The mean of
the nuclear intensity was also routinely analyzed and equivalent results were obtained. The
antibodies used for the analysis were tested with robust controls (shRNAs) to test their
specificity. Where possible, alternative antibodies were tested in control experiments to
confirm the results obtained.
Immunoblot. Protein extracts were resolved by SDS–PAGE and transferred to Protran
nitrocellulose membranes (Whatman, Dassel, Germany). Membranes were blocked in 5%
milk powder, 0.05% Tween-20 in PBS for 1 h and incubated with the primary antibody at 4°C
overnight. Membranes were washed on 0.05% Tween-20 in PBS for 4 x 15 min at room
temperature. Depending on the experiment, sheep anti-mouse HRP or donkey anti-rabbit
HRP (GE Healthcare) were used as secondary antibodies. Antibody binding was visualized
using ECL reagents (GE Healthcare).
Reprogramming of human fibroblasts. Highly purified retroviral particles encoding each of
the human genes OCT4, SOX2, C-MYC and KLF4 were obtained from Vectalys. On day 1,
105 IMR90 cells for each condition were seeded in 6 well plates in medium containing Fetal
Bovine Serum (FBS). The following day the cells were transduced with the four viruses at a
MOI of 10 each for 24 hours. On day 3, the cells were washed three times in PBS and cells
grown in medium containing FBS for three additional days. On day 7, the cells were passaged
to plates containing irradiated MEFs and grown for two more days in medium containing FBS.
After day 9, cells were grown in standard hESC culture conditions (KSR medium: Knock out
DMEM + 20% Serum Replacer + FGF2 4ng/ml). The first hIPSC colonies appeared 15 days
later and were picked 5 days later. Individual colonies were picked and transferred to 12 well
plates containing MEFs feeders in KSR + FGF. Colonies were expanded by enzymatic
dissociation. The resulting hIPSCs lines were characterised for the expression of pluripotency
markers (Oct-4 (Santa Cruz), Sox2 (R&D system), Nanog (R&D system) and Tra-1-60 (Santa
Cruz) by immunostaining.
In vitro differentiation of human IPS. It was performed as described in (Vallier et al. 2009).
Briefly, human ESCs grown in feeder free and serum free conditions were harvested using 1
mg/ml Dispase then split into plates pre-coated with fibronectin. hIPSCs were grown for the
first two days in CDM supplemented with recombinant Activin (Kindly provided by Marko
Hyvonen) and FGF2 (12 ng/ml, R&D systems). To obtain extra-embryonic tissue, hIPSCs
were grown for 7 days in CDM in the presence of BMP4 (10 ng/ml) and SB431542 (10
microM, Tocris). To obtain neuroectoderm progenitors, hESCs were grown in CDM in the
presence of SB431542 (10 µM Tocris) and FGF2 (12 ng/ml, R&D systems) and Noggin (200
ng/ml) for 10 additional days. The resulting cells were grown in non-adherent conditions for 10
Supplementary Materials Banito et al. p3
days and then plated back for 5 additional days in CDM to obtain fully differentiated neuronal
cells. To obtain mesendoderm precursors, hIPSCs were grown for the 3 following days in
CDM in the presence of BMP4 (10ng/ml, R&D systems), FGF2 (20 ng/ml, R&D systems) and
Activin (100 ng/ml, R&D systems) and LY29002 (10 µM, Promega).
Supplementary Materials Banito et al. p4
SUPPLEMENTARY FIGURE LEGENDS
Supplementary Figure S1. The expression of the four reprogramming factors from a
polycistronic vector or from 4 independent plasmids induces growth arrest in IMR90
human fibroblasts. A. Expression of the 4 reprogramming factors (Sox2, Oct4, Klf4 and c-Myc) using the
polycistronic cassette (Carey et al. 2009) cloned in pBABE was confirmed by
immunofluorescence in IMR90 cells.
B. Quantification of BrdU incorporation in IMR90 transduced with OSKM construct (OSKM),
with the 4 factors in independent plasmids (4F) and controls.
C. Quantification of SA-βGal positive cells in IMR90 infected with OSKM, 4F and controls
(Left). Representative microphotographs showing that cells infected with OSKM or 4F display
SA-βGal activity (Right). This figure is an extension of the experiment presented in Fig. 1E.
D. Quantification of the percentage of cells in different stages of the cell cycle as analyzed by
PI staining followed by flow cytometry.
E. Expression of the 4 reprogramming factors in IMR90 cells do not induce a significant
amount of apoptosis as estimated by IF using an antibody recognizing cleaved caspase 3.
The positive control is IMR90 cells treated with cyclohexamide (100 µg/ml) for 1h and TNF α
(50 ng/ml) for 18 hours.
Supplementary Figure S2. Expression of the 4 reprogramming factors induces
senescence in BJs and MEFs.
A. Crystal Violet stained plates (top panels) and bright field images (middle) showing the
arrest induced in BJs (human foreskin fibroblasts) as compared with the empty vector and
cells expressing a hairpin against p21CIP1 (105 cells were seeded after selection and fixed 14
days later). Analysis of mRNA levels for p53, p21CIP1 (CDKN1a) and p16INK4a (INK4a) in the
indicated cells (bottom).
B. Crystal Violet stained plates of MEFs infected with the 4 factors (pMXs-Oct4, pMXs-Sox2,
pMXs-Klf4 and pMXs-Myc T58A) and with a hairpin targeting p16Ink4a/p19Arf (105 cells were
seeded and fixed 15 days later). Protein levels of p21CIP1 and p16INK4a were determined by
Western blot.
Supplementary Figure S3. Dissecting the effect of the individual reprogramming
factors on senescence. A. Expression of reprogramming factors (Sox2, Oct4, Klf4 and c-Myc) affects the cell growth
of IMR90 human diploid fibroblasts. Cells were transduced using pBABE retroviral plasmids
encoding the 4 factors and selected for 6 days. 105 cells were seeded per 10 cm dish, fixed
and stained with crystal violet 15 days later.
B. Growth curve of IMR90 infected with the each reprogramming factors, Nanog and controls.
Cells were seeded in triplicate in 24-well plates; one plate was fixed every two days and
Supplementary Materials Banito et al. p5
stained with crystal violet. The relative cell number corresponds to the absorbance at each
time point relative to absorbance at day 0 (day after seeding, Left panel). Quantification of
BrdU incorporation in IMR90 cells infected individually with the reprogramming factors (12
days post infection, right panel).
C. Quantification of the SA β-gal positive cells and representative microphotographs showing
an increase in SA β-gal positive cells after expression of the individual reprogramming factors.
Oncogenic RAS induces SA β-gal, while infection with an shRNA targeting p53 or with Nanog
does not.
D. Control immunofluorescence showing Nanog expression.
Supplementary Figure S4. High content analysis of protein expression by immunofluorescence.
IMR90 cells infected with empty vector and RasV12 were seeded in 96-well plates at a
density of 4,000 cells per well. The following day, cells were stained by immunofluorescence
for p16INK4a and DAPI (nucleus) and subjected to High Content Analysis (HCA). To create a
Threshold Filter to distinguish cells expressing high or low levels of p16INK4a we generated a
cut-off based on the histograms of p16INK4a nuclear intensity (Nuc Intensity Reference 2) for
cells infected with empty vector (A), RasV12 (B) or both (C). In this example the cut-off was
set above a value of nuclear intensity of 235.
Supplementary Figure S5. Upregulation of DNA damage, oxidative stress and
senescence markers in response to expression of the 4 reprogramming factors.
A. 8-oxo-Guanine levels increase in response to expression of the 4 reprogramming factors.
Detection of 8 oxo-guanine (a common DNA lesion resulting from oxidative stress) in IMR90s
infected with OSKM and controls.
B-E. Expression of the 4 reprogramming factors results in an increase in the cells positive for
DNA damage (as measured by pST/Q IF), p53, p21CIP1 and p16INK4a. Representative images
are shown of the experiment quantified in Fig. 2A-D.
Supplementary Figure S6. Induction of p16Ink4a and p21Cip1 upon expression of the 4
reprogramming factors in MEFs.
The graphs presented were generated from data published by (Mikkelsen et al. 2008). The
latter refers to gene expression profiles obtained during doxycycline treatment (days 4, 8, 12,
and 16) of MEFs carrying integrated doxycycline-inducible lentiviral vectors expressing the
four reprogramming factors. Expression levels of p16INK4a and p21CIP1 upon Dox treatment
are relative to the levels of expression in day 0.
Supplementary Figure S7. Time course for the expression of p53, p21CIP and p16Ink4a in
IMR90 cells expressing the 4 reprogramming factors.
Supplementary Materials Banito et al. p6
The levels of p53, p21CIP and p16Ink4a were determined by immunofluorescence over the
course of 10 days. The time line corresponds to the one presented in Figure 1.
Supplementary Figure S8. Upregulation of senescence effectors during heterokaryon-based reprogramming.
A. Cartoon summarizing the system.
B. Expression of human transcripts linked to pluripotency is upregulated after cell fusion.
C. Upregulation of human INK4a (encoding for p16INK4a) and human CDKN1a (encoding for
p21CIP1) transcripts during reprogramming induced by heterokaryon formation between
human B cells (hB) and mouse ES cells. Human ES cells (hES).
D. Levels of human HPRT as a control.
Supplementary Figure S9. Levels of p16Ink4a and p21Cip1 are elevated in partially
reprogrammed iPS cells when compared with fully reprogrammed iPS cells.
A. RNA samples from incompletely and fully reprogrammed mouse embryonic fibroblasts
(MEFs) were analyzed by qRT-PCR for the expression of the cyclin dependent kinase
inhibitors p16Ink4a (Ink4a) and p21Cip1 (Cdkn1a). Pre-IPS samples exhibit ES cell morphology,
but do not express all pluripotency associated genes, maintain the expression of viral
transgenes, retained the epigenetic silencing of the X chromosome, are irresponsive to LIF
and are unable to colonise chimeras.
B. Values were obtained from gene expression profiling data presented in Supplemental
Material of (Mikkelsen et al. 2008). Values of expression for p16Ink4a (Ink4a) and p21Cip1
(Cdkn1a) in partially reprogrammed cell lines (MCV6 and MCV8), IPS cell line (MCV8.1) and
ES cells are relative to expression levels in MEFs. Partially reprogrammed cells
characteristics are defined in detail in (Mikkelsen et al. 2008).
C. Values presented for p16Ink4a and p21Cip1 correspond to the logarithm (base 2) of the
expression in partially reprogrammed (Pre-iPS) and ES and were obtained from
Supplemental Data (Table S1) of (Sridharan et al. 2009). The values are normalized to the
expression in ES cells.
Supplementary Figure S10. ChIP analysis of the INK4a/ARF locus in IMR90s expressing
the 4 reprogramming factors from independent plasmids (4F).
A, B. Expression of the 4 reprogramming factors from independent plasmids (4F), results in a
loss of H3K27me3 marks and an increase in H3K4me3 marks in the INK4b/ARF/INK4a locus,
as seen with OSKM cells (Figure 3).
C. Expression of the 4 reprogramming factors results in increased recruitment of RNA pol II to
the INK4a promoter.
Supplementary Figure S11. Upregulation of RBL2 (p130) during reprogramming and
effect of expressing miR-302a-d.
Supplementary Materials Banito et al. p7
A. RBL2 (p130) is upregulated during reprogramming-induced senescence. IMR90s infected
with OSKM vector were subjected to immunofluorescence using antibodies recognizing p130
(RBL2, retinoblastoma-like protein 2).
B-C. Infection with a vector expressing miRNAs miR-302a-d prevents the upregulation of
p21CIP1a and p130 in response to the 4 reprogramming factors. Representative images of the
data shown in Fig. 4D, E.
Supplementary Figure S12. Comparison of the expression levels of ES cells specific
microRNAs during RIS and in iPS cells.
miR-302b, is detected at lower levels in OSKM arrested cells when compared to iPS or
human ES cells, exhibiting the same expression pattern as the related miRNAs, miR-302a,
miR-302c and miR-302d (Figure 4). Values are relative to IMR90 cells infected with a control
vector. miR-372 and miR-373, which also target CDKN1a (encoding for p21CIP1) and RBL2
(encoding for p130), are undetected in human fibroblast as well as in OSKM arrested cells.
Values are normalized to hES cells; u.d.l., under the detection limit.
Supplementary Figure S13. Inhibition of senescence effectors improves
reprogramming efficiency of BJ and IMR90 cells.
A. Colonies of the reprogramming experiment performed with BJ human fibroblast and
described in Fig.5, were analyzed by immunofluorescence for NANOG and TRA-1-60
expression. Representative pictures of double positive colonies are shown. The quantification
is presented in Fig. 5B.
B. Bright filed images showing morphology of fully and partially reprogrammed colonies
derived from BJ cells.
C. Count of partially reprogrammed colonies in BJs (human foreskin fibroblasts) empty vector
and with knockdown for p53, p21Cip1and p16Ink4a.
D. IMR90 human fibroblasts were infected with the indicated viruses and cells selected. Q-
RT-PCR showing the levels of the transcripts for p53, CDKN1A (encoding for p21CIP1) and
INK4a (encoding for p16INK4a) in the cells used for the reprogramming experiments.
E, F. Count of partially (E) and fully (F) reprogrammed colonies. IMR90 fibroblasts expressing
shRNAs targeting p16INK4a, p21CIP1 or p53 were transduced with lentiviruses expressing Oct-4,
Sox2, Klf4 and c-Myc and grown in culture conditions compatible with pluripotent stem cells
growth. Partially or fully reprogrammed colonies (as defined by morphological characteristics)
were counted 3 weeks after transduction. Number of colonies is shown as the mean ± SD
from three informative experiments. Microphotographs of representative colonies are shown
at the right side.
G. Fully reprogrammed colonies generated from IMR90 fibroblasts expressing shRNA
targeting p16INK4a were picked and expanded. After amplification, immunostaining analysis
was performed to detect the expression of the pluripotency markers Oct4, Sox2, Nanog and
Tra-1-60.
Supplementary Materials Banito et al. p8
Supplementary Figure S14. Enhanced efficiency of reprogramming in MEFs knockout
or knockdown for senescence effectors.
A. MEFs were infected with the indicated vectors and selected. Q-RT-PCR showing the levels
of the transcripts for Tp53, Cdkn1a (encoding for p21Cip1) and Ink4a (encoding for p16Ink4a) in
the cells used for the reprogramming experiments showed in (B).
B. MEFS expressing shRNAs targeting p16INK4a/p19Arf, p21CIP1 or p53 were transduced with
lentiviruses expressing Oct-4, Sox2, Klf4 and c-Myc and grown in culture conditions
compatible with pluripotent stem cells growth. The number of alkaline phosphatase (AP)
positive colonies obtained after seeding 35,000 cells was quantified.
C. Wildtype (WT) MEFs or MEFs knockout for p53, p21 (p53-/-, p21-/-) were transduced with
lentiviruses expressing Oct-4, Sox2, Klf4 and c-Myc, and grown in culture conditions
compatible with pluripotent stem cells growth The number of alkaline phosphatase (AP)
positive colonies obtained after seeding 35,000 cells was quantified.
Supplementary Figure S15. iPS-2 and iPS-3 clones derived from BJs shp16 and shp53
express pluripotency related genes.
qRT-PCR for hDNMT3b, hRex1, hCripto and hTert in BJs and IPS-2 (derived from BJs
shp16) and iPS-3. Values are relative to iPS2. These are representative q-RT-PCR of the
data summarized in the table presented in Fig. 5D.
Supplementary Figure S16. Senescence as an early barrier for reprogramming.
Reprogramming induced senescence (RIS) is an early barrier to the process. Partially
reprogrammed (Pre-iPS) cells are trapped in a late state in the reprogramming process due to
incomplete epigenetic resetting. Strategies including inhibition of DNA methylation,
knockdown of lineage specific genes (Mikkelsen et al. 2008) or treatment with 2 inhibitors
(Silva et al. 2008) can convert Pre-iPS cells to fully reprogrammed iPS cells or increase the
proportion of fully vs. partially reprogrammed cells (middle panel). Here, we show how
knocking down critical senescence effectors results in increased numbers of both partially and
fully reprogrammed cells, presumably by reducing the proportion of cells that succumb to the
first barrier (right panel).
Supplementary Materials Banito et al. p9
SUPPLEMENTARY REFERENCES
Carey, B.W., Markoulaki, S., Hanna, J., Saha, K., Gao, Q., Mitalipova, M., and Jaenisch, R. 2009. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 106(1): 157-162.
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, B.E., Jaenisch, R., Lander, E.S., and Meissner, A. 2008. Dissecting direct reprogramming through integrative genomic analysis. Nature 454(7200): 49-55.
Pereira, C.F., Terranova, R., Ryan, N.K., Santos, J., Morris, K.J., Cui, W., Merkenschlager, M., and Fisher, A.G. 2008. Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2. PLoS Genet 4(9): e1000170.
Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T.W., and Smith, A. 2008. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 6(10): e253.
Sridharan, R., Tchieu, J., Mason, M.J., Yachechko, R., Kuoy, E., Horvath, S., Zhou, Q., and Plath, K. 2009. Role of the murine reprogramming factors in the induction of pluripotency. Cell 136(2): 364-377.
Vallier, L., Touboul, T., Chng, Z., Brimpari, M., Hannan, N., Millan, E., Smithers, L.E., Trotter, M., Rugg-Gunn, P., Weber, A., and Pedersen, R.A. 2009. Early cell fate decisions of human embryonic stem cells and mouse epiblast stem cells are controlled by the same signalling pathways. PLoS One 4(6): e6082.
Supplementary Materials Banito et al. p10
Supplementary Table I. Details of plasmids generated for this study.
Vector Insert cloned from Addgene number Reference
pBABEpuro-OSKM TetO-FUW-OSKM Addgene 20321 Carey et al., 2009
pBABEpuro-SO FUW-SO Addgene 20329 Carey et al., 2009
pBABEpuro-Oct4 pMXs-Oct3/4 Addgene 13366 Takahasi and Yamanaka, 2006
pBABEpuro-Sox2 pMXs-Sox2 Addgene 13367 Takahasi and Yamanaka, 2006
pBABEpuro-Klf4 pMXs- Klf4 Addgene 13370 Takahasi and Yamanaka, 2006
pBABEpuro-Nanog pMXs- Nanog Addgene 13354 Takahasi and Yamanaka, 2006
Supplementary Materials Banito et al. p11
Supplementary Table II. Details of oligonucleotide primers used in this study.
Primers used for qRT-PCR Target Forward primer Reverse primer Human p16: CGGTCGGAGGCCGATCCAG GCGCCGTGGAGCAGCAGCAGCT (Run at 66°C) Human p53: CCGCAGTCAGATCCTAGCG AATCATCCATTGCTTGGGACG Human p21: CCTGTCACTGTCTTGTACCCT GCGTTTGGAGTGGTAGAAATCT Human Oct4: TCGAGAACCGAGTGAGAGGC CACACTCGGACCACATCCTTC Human Nanog: CCAACATCCTGAACCTCAGCTAC GCCTTCTGCGTCACACCATT Human Cripto: AGAAGTGTTCCCTGTGTAAATGCTG CACGAGGTGCTCATCCATCA Human HPRT: TCCTTGGTCAGGCAGTATAATCC GTCAAGGGCATATCCTACAACAAA Human GAPDH: TGATGACATCAAGAAGGTGGTG TCCTTGGAGGCCATGTGGGCCA Human RPS14: TCACCGCCCTACACATCAAACT CTGCGAGTGCTGTCAGAGG Mouse p21: CCTGGTGATGTCCGACCTG CCATGAGCGCATCGCAATC Mouse p53: CACGTACTCTCCTCCCCTCAAT AACTGCACAGGGCACGTCTT Mouse p16: GTGTGCATGACGTGCGGG GCAGTTCGAATCTGCACCGTAG Mouse RPS14: GACCAAGACCCCTGGACCT CCCCTTTTCTTCGAGTGCTA TaqMan probes Target Applied Biosystems Reference Human mir-302a 529 Human mir-302b 531 Human mir-302c 533 Human mir-302d 535 Human mir-372 560 Human mir-373 561 Human RNU 48 1006 Human JMJD3 Hs 00389749_m1 Human GAPDH 4333764-0803023
Primers used for generating shRNA constructs:
Human p21, forward oligo:
TCCCACAATGCTGAATATACAGATCCCCTCCCACAATGCTGAATATACATTCAAGAGATGTATATTCAG
CATTGTGGGATTTTTA
Human p21, reverse oligo:
AGCTTAAAAATCCCACAATGCTGAATATACATCTCTTGAATGTATATTCAGCATTGTGGGAGGG
Supplementary Materials Banito et al. p12
Supplementary Table III. Details of antibodies used in this study. Target Source BrdU A21300, Invitrogen
Human p16INK4a JC-8, CRUK,
Human p53 DO-1, sc-126, Santa Cruz Biotechnology
Human γH2AX 05-636, Upstate
Human pST/Q 2851, Cell Signaling
Human and mouse β- Actin sc-47778, Santa Cruz Biotechnology
Human p21 CIP1 18209, Abcam
Human and mouse p21CIP1 p1484, Sigma
Human JMJD3 ARP40102, Aviva
Human and mouse Oct4 sc-5279, Santa Cruz Biotechnology
Mouse Sox2 15830, Abcam
Human and mouse Klf4 34814, Abcam
Human and mousec-Myc ssc-764, Santa Cruz Biotechnology
8 oxo-guanine Mab3560, Millipore
Human Cleaved Caspase-3 9664, Cell Signaling
Human Tra-81 56000017, BD Pharmingen
Human Tra-60 sc-21705, Santa Cruz Biotechnology
Mouse Nanog REC-RCAB0002PF, CosmoBio
Human Pax6 PRB-278P-100, Covance
Human CDX2 MU392A-UC, BioGenex
Human Gata6 ab22600, Abcam
Human Sox2 AF2018, R&D
Human Sox1 AF3369, R&D
Human Brachyury AF2085, R&D
Human Sox17 AF1924, R&D
GENESDEV/2009/121525/Banito_Fig S1
4 Factors
% P
ositi
ve c
ells
Vector RASshp53OSKM 4-F0
10203040506070
BrdU
SA β-Gal
01020304050607080
Vector RASshp53OSKM 4-F
% P
ositi
ve c
ells
D E
0
10
20
30
40
50
60
G1 S G2
Vector
OSKMRAS
shp53
% C
ells
0102030405060708090
TNF+CHX
Vector RASOSKM shp53
% P
ositi
ve c
ells
Cleaved Caspase 3
C
A
B
Vector OSKM
RAS
Vector OSKM shp21
Vector OSKM shp21
0
1
2
3
4
Vector OSKM0
1
2
3
4
Vector OSKM0
1
2
3
4
Vector OSKM
TP53 CDKN1a INK4a
Rel
ativ
e m
RN
A le
vels
A
BVector 4 factors shInk4a/arf
Vector
OSKM4F
p21
p16
β-Actin
GENESDEV/2009/121525/Banito_Fig S2
A
B
Vector RASSox2Oct4 c-MycKlf4
Sox2Oct4 c-MycKlf4
Vector RAS shp53 NanogC
% B
rdU
pos
itive
cel
ls
Vector RASSox2Oct4 Klf4 c-Myc0
5
10
15
20
25
30
35
40
45
D
Vector
Nanog
DAPI Nanog Merge
GENESDEV/2009/121525/Banito_Fig S3
A B C
D
Vector
RAS
GENESDEV/2009/121525/Banito_Fig S4
05
1015202530354045
VectorOSKMRAS shp53
8oxoG
% P
ositi
ve c
ells
DAPI OxoG Merge
Vector
OSKM
GENESDEV/2009/121525/Banito_Fig S5
p21CIP1DAPI Merge
Vector
OSKM
DAPI p16INK4a
Vector
OSKM
DAPI p53 Merge
Vector
OSKM
DAPI pST/Q Merge
Vector
OSKM
Merge
A
B C
D E
0123456789
0
5
10
15
20
25
30
Ctrl 4 8 12 16
Ink4a
Time after Dox. Induction (d)
Ctrl 4 8 12 16Rel
ativ
e m
RN
A le
vels
Cdkn1a
Time after Dox. Induction (d)
Rel
ativ
e m
RN
A le
vels
GENESDEV/2009/121525/Banito_Fig S6
p53
p21
p16
GENESDEV/2009/121525/Banito_Fig S7
C
D
B
AR
elat
ive
mR
NA
leve
lsR
elat
ive
mR
NA
leve
ls
Rel
ativ
e m
RN
A le
vels
Rel
ativ
e m
RN
A le
vels
Rel
ativ
e m
RN
A le
vels
Rel
ativ
e m
RN
A le
vels
GENESDEV/2009/121525/Banito_Fig S8
0
10
20
30
40
50
60
Rel
ativ
e m
RN
A le
vels
Ink4a
0
0.5
1
1.5
2
2.5
Rel
ativ
e m
RN
A le
vels
Cdkn1a
MEFs Pre-iPS ES MEFs Pre-iPS ES
A
B
C
00.5
11.5
22.5
33.5
ESPre-IPS
02468
1012141618
Rel
ativ
e m
RN
A le
vels
0
1
2
3
4
5
6R
elat
ive
mR
NA
leve
ls
00.5
11.5
22.5
33.5
ESPre-IPS
Rel
ativ
e m
RN
A le
vels
MEFs MCV6 MCV8 iPS ESPre-iPS
Ink4a Cdkn1a
MEFs MCV6 MCV8 iPS ESPre-iPS
Cdkn1aInk4a
Rel
ativ
e m
RN
A le
vels
GENESDEV/2009/121525/Banito_Fig S9
0
0.05
0.1
0.15
0.2
0.25
1 3 5 7 12
Vector4F
0
0.05
0.1
0.15
0.2
0.25
Vector4F
H3K4me3
H3K27me3H
3K27
me3
/Tot
al H
3H
3K4m
e3/T
otal
H3
2 4 6 8
1 3 5 7 122 4 6 8
Primer sets:
Primer sets:
GENESDEV/2009/121525/Banito_Fig S10
A
B
C
00.05
0.10.15
0.20.25
0.30.35
RNA pol II
Sign
al/T
otal
H3
hES
VectorOSKM
INK4a pr. 3’ regionp.s. 6 p.s. 12
DAPI p130 Merge
Vector
OSKM
p130
GENESDEV/2009/121525/Banito_Fig S11
OSKM
Ctrl. 302Vector
DAPI
p21CIP1
DAPI
p130
OSKMCtrl. 302Vector
A
B
C
u.d.l.u.d.l.
u.d.l.
GENESDEV/2009/121525/Banito_Fig S12
G
0
20
40
60
80
100
120
pRS shp16
Rel
ativ
e m
RN
A le
vels
0
20
40
60
80
100
120
pRS shp53
Rel
ativ
e m
RN
A le
vels
0
20
40
60
80
100
120
pRS shp21 shp53
Rel
ativ
e m
RN
A le
vels
A
Oct-4 Sox2 Nanog Tra-1-60
p53 CDKN1a INK4a
E
F
Col
onie
s
0
2
4
6
8
10
12
Vector shp16 shp21 shp53
Fully Reprogrammed (IMR90)
Col
onie
s
Partially Reprogrammed (IMR90)
050
100150200250300350400450500
Vector shp16 shp21 shp53
hiPSCs derived from IMR90-shp16
0
40
80
120
160
200
Vector shp53 shp21 shp16
Nan
og a
nd T
RA
-1-6
0 n
egat
ive
colo
nies
Partial Reprogrammed (BJs)
D
IMR90
FullyReprogrammed
PartiallyReprogrammed
GENESDEV/2009/121525/Banito_Fig S13
Vector shp16 shp21 shp53
NA
NO
GTR
A-1
-60
DA
PI
B
C
BJBJ
A
B
0200400600800
10001200140016001800
Vector shp53 shp21 shInk4a/Arf
0
0.2
0.4
0.6
0.8
1
1.2
Vector shp53
Tp53
0
0.2
0.4
0.6
0.8
1
1.2
Vector shp21
Cdkn1a
0
0.2
0.4
0.6
0.8
1
1.2
Vector shInk4a/Arf
Ink4a
Rel
ativ
e m
RN
A le
vels
MEFs
AP p
ositi
ve c
lolo
nies
mouse iPS
0
200
400
600
800
1000
1200
1400
WT p53-/- p21-/-
AP
Posi
tive
Col
onie
s
Cmouse iPS
GENESDEV/2009/121525/Banito_Fig S14
GENESDEV/2009/121525/Banito_Fig S15
‘Standard’ Reprogramming
Low efficiency
SOMATIC CELLS
Senescence
Intermediate State
iPS CELLSPre-iPS
Inhibition of senescence
Increased numbersof both Fully and
Partialreprogrammed iPS
SOMATIC CELLS
Senescence
Intermediate State
iPS CELLSPre-iPS
Inhibition of DNA methylation
Increased proportionof Fully vs. Partialreprogrammed iPS
SOMATIC CELLS
Senescence
Intermediate State
iPS CELLS
Pre-iPS
GENESDEV/2009/121525/Banito_Fig S16